Eli Lilly and Company (LLY) Lilly To Acquire Orna Therapeutics To Advance Cell Therapies
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
59 articles, transcripts, and reports
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
Eli Lilly and Company (NYSE: LLY) Q4 2025 Earnings Conference
Eli Lilly and Company (NYSE: LLY) reported its fourth quarter 2025 earnings results today. Revenue increased 43% year-over-year to $19.3 billion. Reported net income increased 50%…
Eli Lilly and Company (NYSE: LLY) Q2 2025 Earnings Call dated Aug. 07, 2025 Corporate Participants: Mike Czapar — Investor Relations David A. Ricks —…
Eli Lilly and Company (NYSE: LLY) Q3 2025 Earnings Call dated Oct. 30, 2025 Corporate Participants: Mike Czapar — Senior Vice President of Investor Relations…
Eli Lilly and Company (NYSE: LLY) reported its third quarter 2025 earnings results today. Worldwide revenue was $17.60 billion, up 54% from the same period…
Eli Lilly and Company (NYSE: LLY) reported its second quarter 2025 earnings results today. Worldwide revenue was $15.56 billion, up 38% from the same period…
Eli Lilly and Company (NYSE: LLY) had a positive start to fiscal 2025, reporting strong revenue and earnings growth for the first quarter. The company…
Eli Lilly and Company (NYSE: LLY) reported its first quarter 2025 earnings results today. Worldwide revenue was $12.73 billion, up 45% compared to the same…
Eli Lilly and Company (NYSE: LLY) reported its third quarter 2024 earnings results today. Worldwide revenue was $11.44 billion, up 20% compared to the same…